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IMPLEMENTATION AND OPERATIONAL RESEARCH: EPIDEMIOLOGY AND PREVENTION
Immunodeficiency at the Start of Combination
Antiretroviral Therapy in Low-, Middle-, and
High-Income Countries
The IeDEA and ART Cohort Collaborations
Objective: To describe the CD4 cell count at the start of
combination antiretroviral therapy (cART) in low-income (LIC),
lower middle-income (LMIC), upper middle-income (UMIC), and
high-income (HIC) countries.
Methods: Patients aged 16 years or older starting cART in a clinic
participating in a multicohort collaboration spanning 6 continents
(International epidemiological Databases to Evaluate AIDS and ART
Cohort Collaboration) were eligible. Multilevel linear regression
models were adjusted for age, gender, and calendar year; missing
CD4 counts were imputed.
Results: In total, 379,865 patients from 9 LIC, 4 LMIC, 4 UMIC,
and 6 HIC were included. In LIC, the median CD4 cell count at
cART initiation increased by 83% from 80 to 145 cells/mL between
2002 and 2009. Corresponding increases in LMIC, UMIC, and HIC
were from 87 to 155 cells/mL (76% increase), 88 to 135 cells/mL
(53%), and 209 to 274 cells/mL (31%). In 2009, compared with LIC,
median counts were 13 cells/mL [95% conﬁdence interval (CI): 256
to +30] lower in LMIC, 22 cells/mL (262 to +18) lower in UMIC,
and 112 cells/mL (+75 to +149) higher in HIC. They were 23 cells/mL
(95% CI: +18 to +28 cells/mL) higher in women than men. Median
counts were 88 cells/mL (95% CI: +35 to +141 cells/mL) higher in
countries with an estimated national cART coverage.80%, compared
with countries with ,40% coverage.
Conclusions: Median CD4 cell counts at the start of cART
increased 2000–2009 but remained below 200 cells/mL in LIC and
MIC and below 300 cells/mL in HIC. Earlier start of cART will
require substantial efforts and resources globally.
Key Words: antiretroviral therapy, CD4 cell count, sub-Saharan
Africa, North America, Carribean, Central and South America,
Europe, Asia/Paciﬁc
(J Acquir Immune Deﬁc Syndr 2014;65:e8–e16)
INTRODUCTION
The prognosis of HIV-positive patients has dramatically
improved with the advent, in 1996, of combination antire-
troviral therapy (cART).1,2 Suppressed viral replication allows
reconstitution of the immune system: peripheral CD4 cell
counts increase rapidly ﬁrst from redistribution from lym-
phoid tissues and then gradual by de novo synthesis.3,4 Since
2002, the Global Fund for Tuberculosis, AIDS, and Malaria;
US President’s Emergency Plan for AIDS Relief (PEPFAR);
and other funders have sharply increased global cART avail-
ability. The World Health Organization (WHO) estimated, by
2010, that 6.6 million of the 15 million who needed cART in
low- and middle-income countries had access.5
When to initiate cART to maximize the beneﬁt of
therapy has been debated for years.6 Beneﬁts of early initia-
tion, at high CD4 cell counts, must be balanced against drug
toxicities and the potential for drug resistance. Conversely,
starting therapy late, as measured clinically or by CD4 count,
is associated with poorer prognosis and increased mortality.7
A substudy of the Strategies for Management of Antiretrovi-
ral Therapy trial showed that delaying cART until the count
fell below 250 cells/mL more than tripled the rate of AIDS or
death compared with starting above 350 cells/mL.8 Analyses
that combined data from cohort studies also indicated that
starting cART above 350 CD4 cells/mL is beneﬁcial, and
some, but not all, showed beneﬁt with a threshold of
500 cells/mL.9–11 The START (NCT00821171) and TEMPRANO
(NCT00495651) trials will provide further data on the efﬁ-
cacy of early versus late initiation of cART.
However, many patients enter care late. An analysis of
treatment programs in 12 countries in sub-Saharan Africa,
South America, and Asia showed that while CD4 cell counts
at initiation increased from 2001 to 2005/2006, most patients
started well below recommended thresholds.12 Similarly, an
US cohort and a Canada cohort showed that median CD4 cell
count at ﬁrst presentation for HIV care was 317 cells/mL
in 2007: more than half of patients initiated therapy below
350 cells/mL.13 A recent Latin American study reported that
the percentage of patients initiating cART late ranged from
56% in Argentina to 91% in Honduras.14
Early initiation of cART is recognized as having a
broader role in HIV prevention.15 Already established as
a means to prevent mother-to-child transmission (PMTCT),5
the HIV Prevention Trials Network 052 trial found that cART
reduced heterosexual HIV transmission by 96% between dis-
cordant couples.16 Combined with other proven prevention
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tools, immediate or early cART might contribute to achieving
the goal of an AIDS-free generation.17
We examined trends and determinants of the CD4 cell
count at cART initiation in patients starting therapy between
2002 and 2010 in low-, middle-, and high-income countries
by combining data from 2 HIV cohort consortia, which
together span 6 continents.
METHODS
Data Sources
The International epidemiological Databases to Evalu-
ate AIDS (IeDEA) is a global consortium structured through
regional centers to pool clinical and epidemiological data on
HIV-positive individuals, particularly patients on cART. The
7 regions included in IeDEA are North America, Caribbean/
Central and South America, Asia/Paciﬁc, East Africa, West
Africa, Central Africa, and Southern Africa. Regional cohorts
of IeDEA have been described in detail elsewhere.18–21 The
European cohorts of the ART Cohort Collaboration, a network
of cohort studies of patients on cART in high-income coun-
tries (HIC), were also included.7 Pooling of data and their use
in collaborative analyses were approved by local ethics com-
mittees and institutional review boards. For the present study,
regional centers sent de-identiﬁed data to the University of
Bern, Switzerland, for cleaning and analysis.
Inclusion Criteria and Definitions
Patients aged 16 years or older at cART initiation were
eligible. cART was deﬁned as a regimen of at least 3
antiretroviral drugs, typically from 2 drug classes. Baseline
CD4 cell count was deﬁned as the count nearest to the date of
cART start with a window of 6 months before to 1 month
after starting. CD4 cell counts above 5000 cells/mL (ie, .3
times above the upper reference range in whites22) were con-
sidered invalid and set to missing. Countries were grouped
according to the World Bank classiﬁcation of Gross National
Income per Capita 2010 as low-income countries (LIC, US
$1005 or less per year), lower middle-income countries
(LMIC, US$1006 to 3975 per year), upper middle-income
countries (UMIC, US$3976 to 12,275 per year), and high-
income countries (HIC, US$12,276 or more per year).23 Data
on national cART coverage for 2009 (based on the WHO
2006 treatment guidelines24) were obtained from the 2010
progress report on the Global HIV/AIDS response published
by WHO25 for LIC and MIC.
Statistical Analyses
Descriptive analyses were stratiﬁed by country, gender,
and World Bank country income group. CD4 cell counts at
cART start and other baseline characteristics were summa-
rized as medians with interquartile ranges or numbers with
percentages. To address the problem of generalizing data
from a small sample to an entire country, further analyses
were restricted to countries that contributed at least 500
patients with CD4 cell counts from 2 or more sites and had
observations after 2007.
Missing CD4 counts were multiply imputed using
predictive mean matching and chained equations stratiﬁed
by gender, age, and country income level. Technical details
on the multiple imputation are provided in the Supplemental
Digital Content (see http://links.lww.com/QAI/A446). All
analyses were performed both for the imputed data and for
the complete case dataset. To assess trends and examine indi-
vidual-level and country-level predictors of median baseline
CD4 cell counts, we aggregated the data by sex, age, year,
and country. We then ﬁtted 3 types of weighted linear regres-
sion models. First, a simple linear regression estimated
gender-speciﬁc annual changes in median baseline CD4 cell
counts by country (model 1). In sensitivity analyses, we
weighted individual country data to create a data set that
was representative, within each income group, of the number
of patients on cART in each country in 2009, as estimated
by WHO.5 The derivation of the weighting factors is
shown in Table S1 (see Supplemental Digital Content,
http://links.lww.com/QAI/A446).
Second, a weighted mixed-effects linear regression was
used to estimate the median CD4 cell counts at the start of
cART in 2009 and to examine the inﬂuence of age, sex,
country income level, and, in an analysis restricted to LIC and
MIC, of national cART coverage (model 2). Age, calendar
year, gender, and country income level were entered as ﬁxed
effects and country as random effect. The third model
included calendar year, gender, and country income level
and was used to model median CD4 cell count trends between
2002 and 2010 (model 3). Finally, the proportions of patients
starting cART with CD4 cell counts below 50, 100, and 200
cells/mL were analyzed using generalized linear mixed effects
models. Age, calendar year, gender, and country income level
were entered as ﬁxed effects and intercept and slope as ran-
dom effects, by country. Data were analyzed using Stata 12.0
(Stata Corporation, College Station, TX) and R 2.12 (The R
Development Core Team, Vienna, Austria).
RESULTS
Descriptive Analyses
Data from 492,915 patients aged 16 years or older who
started cART in 48 countries were submitted to the data center
(Fig. 1). Among 437,230 ART-naive patients with known age,
gender, and start date, 309,564 (63%) had a CD4 cell count at
the start of cART. Compared with the 127,666 patients without
a CD4 cell count, patients with counts at cART initiation were
younger, more likely to be male, and more likely to be from
a high-income country. Importantly, those with CD4 cell
counts were less likely to have advanced disease (WHO stage
III/IV) than patients without CD4 cell counts (see Table S2,
Supplemental Digital Content, http://links.lww.com/QAI/
A446). Only 4.6% (20,217 patients) had an earlier CD4 cell
count, 6 months or more before starting ART.
The number of included patients from each country
varied from 60 from Japan to 147,029 from Zambia (Table 1).
There were 12 countries with up to 500 patients, 23 with
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501–5000 patients, 4 with 5001–10,000 patients, 7 with 10,001–
50,000, and 2 with more than 50,000 patients (see Figure S1,
Supplemental Digital Content, http://links.lww.com/QAI/A446).
The percentage of female patients ranged from 4% in Taiwan
to 73% in Burundi, and median age ranged from 30.9 years in
Indonesia to 41.5 years in Nigeria (Table 1). The median year
of cART initiation ranged from 2000 in Australia and Italy to
2009 in the Philippines. The median CD4 cell count at cART
initiation for the entire study period ranged from 56 cells/mL
in Indonesia to 290 cells/mL in Australia.
Regression Models
A total of 379,865 patients from 23 countries were
included in the regression models, including 86,390 patients
from 9 LIC (23%), 176,858 from 4 LMIC (47%), 82,152
from 4 UMIC (22%), and 34,465 from 6 HIC (9%). The
Democratic Republic of the Congo, Kenya, Malawi, and
Mali were overrepresented when compared with the WHO
estimates of the number of patients on cART in the LIC
included in our study. In contrast, Tanzania and Zimbabwe
were underrepresented. The group of LMIC countries was
dominated by Zambia and that of UMIC countries by South
Africa. Among HIC, France contributed almost half of all
patients, whereas the United States and Italy were under-
represented (see Table S1, Supplemental Digital Content,
http://links.lww.com/QAI/A446).
The annual increase in median CD4 cell counts at the
start of cART initiation from 2002 to 2009, estimated through
linear regression (model 1), varied within and across World
Bank country groups and tended to be greater among women
than men (Table 2). Among LIC, the annual change in median
CD4 cell counts ranged from 214 cells/mL [95% conﬁdence
interval (CI): 237 to +9 cells/mL] among women in the Dem-
ocratic Republic of the Congo to +32 cells/mL (95% CI: +22
to +42 cells/mL) among Rwandan women. For LMIC, the
corresponding range was from 22 cells/mL (95% CI: 214
to +9 cells/mL) among Nigerian men to +13 cells/mL (95%
CI: +8 to +19 cells/mL) among women in Côte d’Ivoire. In
UMIC, the range was from 21 cells/mL (217 to +15 cells/mL)
in Botswana men to +15 cells/mL (95% CI: 0 to +29 cells/mL)
among Brazilian men. Finally, in HIC, the range was from
23 cells/mL (95% CI: 212 to +7 cells/mL) in Australian men
to +16 cells/mL (95% CI: +12 to +20 cells/mL) in Canadian men.
Crude (unweighted) and weighted pooled estimates of annual
increases in CD4 cell count at cART initiation by country group
were generally similar (Table 2). Also, results were similar in
the complete case analysis (see Table S3, Supplemental Dig-
ital Content, http://links.lww.com/QAI/A446).
Table 3 shows estimated median CD4 cell counts at the
start of cART in 2009 by age, gender, and country income
level, as estimated from the mixed effects linear regression
(model 2). Median CD4 cell counts were higher in women
compared with men (difference +23 cells/mL, 95% CI: +18 to
+28 cells/mL) and lower for patients aged 30 to 40 years or
younger (difference 216 cells/mL, 95% CI: 221 to 210 cells/
mL) and 40 to 50 years or younger (difference 217 cells/mL,
95% CI: 224 to 210 cells/mL) compared with those younger
than 30 years. Median counts were similar in LIC, LMIC, and
UMIC but were higher in HIC (difference compared with low-
FIGURE 1. Flow chart of patients included and excluded from analyses.
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TABLE 1. Characteristics of Patients Starting cART by Country and World Bank Income Groups
Country
No. Patients Median Age in Years (IQR)
Median Calendar Year of Starting
cART (IQR)
Median CD4 Cell Count at
Start of cART in Cells/mL
(IQR)
Women Men Women Men Women Men Women Men
Low-income
Benin 413 298 33.8 40.1 2005 2005 119 90
Burkina Faso 822 348 35.7 41.3 2007 2006 182 137.5
Burundi 332 139 36.4 43.0 2009 2009 209.5 157
Cambodia 107 110 33.8 36.6 2005 2005 103 70.5
DR Congo 1828 800 38.5 43.3 2008 2008 145 139.5
Gambia 140 77 37.4 45.0 2006 2006 160 130
Haiti 780 668 38.0 40.0 2004 2004 115.5 92.5
Kenya 19,454 10,571 35.2 39.6 2007 2006 135 109
Malawi 4337 3365 33.3 37.2 2008 2008 150 122
Mali 1020 650 32.7 40.2 2006 2006 134 101
Mozambique 284 177 32.1 37.5 2008 2008 242 204
Rwanda 1500 521 33.8 38.0 2006 2007 218 183
Tanzania 2168 1050 36.5 41.4 2007 2007 107 106
Uganda 4229 2552 34.2 38.3 2007 2007 130 114
Zimbabwe 3112 1388 37.1 39.7 2009 2009 133 96
Overall 40,526 22,714 35.1 (29–41) 39.4 (33–46) 2007 (2006–2008) 2007 (2006–2008) 139 (65–213) 113 (40–186)
Lower middle-income
Cameroon 1821 829 33.9 39.3 2009 2009 158 139
Côte d’Ivoire 8531 4857 34.5 41.1 2006 2005 156 125
Honduras 101 159 35.0 38.0 2005 2005 120 98
India 91 364 31.9 34.1 2004 2003 177 129.5
Indonesia 92 227 29.1 31.4 2008 2008 89.5 45
Nigeria 4728 2678 41.2 41.3 2006 2006 162 127
Philippines 27 234 39.3 30.5 2008 2009 186 180
Senegal 183 126 35.4 42.0 2004 2004.5 122 97.5
Zambia 50,096 32,054 33.5 37.3 2008 2008 150 129
Overall 65,670 41,528 34.5 (28–41) 38.4 (33–44) 2007 (2006–2008) 2007 (2006–2008) 152 (76–228) 128 (55–201)
Upper middle-income
Argentina 208 479 34.0 36.0 2004 2004 181 148
Botswana 549 367 34.3 38.4 2003 2003 140 116
Brazil 371 740 37.0 36.1 2007 2007 208 186
Chile 56 383 34.1 36.6 2003 2003 138 112
China 124 409 38.9 39.6 2005 2007 169.5 91
Malaysia 111 380 34.1 36.2 2007 2008 159 113
Mexico 49 349 35.0 35.0 2004 2004 131 84
Peru 208 495 32.0 35.0 2005 2005 85.5 74
South Africa 32,920 21,673 33.6 39.0 2007 2007 124 111
Thailand 731 907 35.7 36.3 2007 2008 95 89
Overall 35,327 26,182 33.7 (28–39) 38.5 (32–45) 2007 (2006–2008) 2006 (2004–2008) 124 (60–188) 111 (42–180)
High-income
Australia 74 1261 33.7 39.1 2001 1999 280 290
Canada 850 3651 36.0 41.0 2002 2002 210 220
France 10,023 20,739 34.3 38.8 2003 2001 237 233
Germany 269 955 33.9 38.5 2004 2002 177 173
Italy 915 2312 35.4 37.6 2000 2000 265 244
Japan 4 56 46.1 38.1 2006 2007 236 253.5
The Netherlands 1617 5125 32.4 39.4 2003 2002 210 189
Singapore 19 83 33.9 41.4 2004 2003 134 57
South Korea 10 182 41.2 38.0 2003.5 2006 123 222.5
Spain 2596 8406 34.0 36.8 2002 2003 224 201
(continued on next page)
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income countries +112 cells/mL, 95% CI: +75 to +149 cells/mL).
In the analysis restricted to LIC and MIC, those with cART
coverage of 80% or greater (Botswana, Brazil, Cambodia,
Rwanda, and Zambia) had substantially higher CD4 cell counts
at cART initiation (difference +88 cells/mL; 95% CI: +35 to
+141 cells/mL) than countries with a coverage below 40% (Côte
d’Ivoire, Democratic Republic of the Congo, Indonesia, Nigeria,
and Malaysia). Results were again similar in the complete
case analysis (see Table S4, Supplemental Digital Content,
http://links.lww.com/QAI/A446).
Figure 2 shows trajectories of median CD4 cell counts
at cART initiation and the percentage of patients starting
cART below 200 cells/mL and below 100 cells/mL, by country
income group and gender, estimated by model 3. In LIC,
median CD4 cell count at the start of cART increased by
91% in women from 2002 to 2009 (from 82 to 157 cells/mL)
and by 62% (from 79 to 127 cells/mL) in men. Corresponding
increases for LMIC were from 83 to 166 cells/mL in women
(a 102% increase) and from 97 to 138 cells/mL in men (a 42%
increase). The increases in UMIC were from 86 to 141 cells/mL
in women (a 63% increase) and from 91 to 125 cells/mL in men
(a 36% increase). Finally, in HIC, median CD4 cell counts at
cART initiation increased by 26% (from 211 to 266 cells/mL)
in women and by 34% (from 208 to 280 cells/mL) in men.
In LIC, the percentage of patients starting cART below
200 cells/mL declined from 85% in 2002 to 81% in 2009 in
women and from 88% to 70% in men. Corresponding ﬁgures
for LMIC were from 78% to 59% in women and from 79% to
67% in men and for UMIC from 86% to 65% in women and
from 78% to 71% in men. In HIC, the decline was from 46%
to 31% in women and from 49% to 35% in men. For thresh-
old below 100 cells/mL, the declines were from 50% to 28%
in women and from 57% to 36% in men in LIC, from 47% to
27% in women and from 51% to 36% in men in LMIC, from
54% to 31% in women and from 49% to 40% in men in
UMIC, and from 22% to 15% in women and from 27% to
17% in men in HIC. Trends were similar in the complete case
analysis (see Figure S2, Supplemental Digital Content,
http://links.lww.com/QAI/A446).
DISCUSSION
This global analysis of CD4 cell counts at cART
initiation between 2002 and 2010 was conducted in 2 HIV
cohort collaborations, which together span 6 continents.7,18–21
We found that median CD4 cell counts at cART initiation
were substantially higher in HIC, with only small differences
between LIC and MIC. Median CD4 cell counts at the start of
cART increased over the study period in most countries.
These increases were greater in LIC and MIC than in HIC,
and greater in women than in men. Among LIC and MIC,
median CD4 cell counts at the start of cART were substan-
tially higher in the few countries with national cART cover-
age of 80% or above.
In LIC and MIC, the median CD4 cell count remained
well below 200 cells/mL between 2002 and 2009, despite the
2001 WHO recommendation to start when the CD4 gets near
or falls below 200 cells/mL or, in persons with advanced
clinical disease (WHO stage IV), irrespective of the CD4 cell
count.26 Following a 2006 recommendation to consider treat-
ment at CD4 cell counts below 350 cells/mL for patients in
WHO stage III, WHO indicated in 2009 that cART should be
initiated at 350 cells/mL irrespective of clinical symptoms.27
National guidelines in resource-limited settings generally ech-
oed WHO guidelines,28 whereas HIC have more rapidly
increased the CD4 cell count threshold for initiation. Of note,
North American guidelines recently converged in their recom-
mendation that cART should be offered to all HIV-positive
individuals, irrespective of the CD4 cell count.29,30
A substantial rise in HIV testing in many countries,
supported by Global Fund for Tuberculosis, AIDS and Malaria,
PEPFAR, national or state/provincial level governments, and
other donors, may have contributed to increasing CD4 cell counts
at the start of cART. A monitoring and evaluation analysis of
PEPFAR-supported HIV care clinics in 8 sub-Saharan African
countries found that CD4 cell counts at cART initiation increased
with HIV testing coverage in the region.31 In sub-Saharan Africa,
PEPFAR supported over 140 million testing and counseling ses-
sions between 2004 and 2011, with the number of sessions
increasing from 1.9 million in 2004 to over 40 million in
2011.32 Two Demographic and Health Surveys from 7 PEPFAR
countries conducted between 2003 and 2010 showed a dramatic
increase in population level coverage of HIV testing and coun-
seling.32 In Kenya, for example, the percentage of men reporting
testing in the last 12 months increased from 7.5% to 22.7%. The
corresponding increase was even greater in women, from 6.7% to
29.3%. Similarly, in Lesotho, testing increased from 6.3% to
42.0% in women and from 4.8% to 24.0% in men. Provider-
TABLE 1. (Continued ) Characteristics of Patients Starting cART by Country and World Bank Income Groups
Country
No. Patients Median Age in Years (IQR)
Median Calendar Year of Starting
cART (IQR)
Median CD4 Cell Count at
Start of cART in Cells/mL
(IQR)
Women Men Women Men Women Men Women Men
Switzerland 1414 3124 33.9 38.4 2001 2001 201 205
Taiwan 8 186 32.2 32.9 2001.5 2003 132 225
UK 369 1016 34.3 36.9 2003 2002 158 206
USA 3362 8991 39.0 40.0 2003 2003 241.5 215
Overall 21,530 56,087 34.9 (28–41) 38.9 (33–45) 2002 (2000–2004) 2002 (1999–2005) 230 (110–350) 217 (89–345)
Results from complete case descriptive analyses based on 309,564 patients.
IQR, interquartile ranges.
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initiated testing and counseling may not, however, be sufﬁcient
to prevent late HIV diagnosis. Uganda adopted provider-initiated
HIV testing in the health care setting in 2005, but in a recent
randomized controlled trial, half of HIV-positive patients
screened had CD4 cell counts below or equal to 250 cells/mL.33
The steeper increase of HIV testing coverage among
women compared with men may be explained by scale-up of
programs to PMTCT. More frequent testing leads to earlier
diagnosis and then earlier initiation of cART in eligible
women. The scale-up of PMTCT could thus also account for
the greater increases of CD4 cell counts at the start of cART
in women than men observed in the present study. A review
of national program data for 2004 to 2005 showed that the
scale-up of PMTCT had gained momentum in many countries
and that provider-initiated (opt-out) HIV testing had become
nearly universal in some regions (eg, in East and Southern
Africa) but not in others (eg, in West Africa).34 A systematic
review and meta-analysis of 44 studies of pregnant women
who attended PMTCT programs in sub-Saharan Africa
showed that uptake at antenatal care services was 94% for
opt-out testing compared with 58% for opt-in testing.35 Cov-
erage with any type of antiretroviral prophylaxis was 70%,
and 62% of pregnant women eligible for cART received
treatment.35 Similarly, a meta-analysis of 6 studies that re-
ported on numbers of adults followed up between HIV diag-
nosis and start of cART showed that of every 100 patients
with a positive HIV test, 72 had a CD4 cell count measured,
40 were eligible for cART, and 25 started cART. Of note,
men were more likely to be lost to program and less likely to
start cART than women.36
Our study has several limitations. We could only
examine information up to 2010 because more recent data
were not yet available from many sites participating in the
IeDEA and ART cohort collaborations. CD4 cell counts at the
TABLE 2. Annual Change Between 2002 and 2009 in Median
CD4 Cell Count at the Start of cART in LIC, LMIC, UMIC, and
HIC, by Gender
Country
Women Men
CD4 Cells/mL
(95% CI)
CD4 Cells/mL
(95% CI)
Low-income
Benin +8 (215 to +31) +4 (211 to +19)
DR Congo 214 (237 to +9) +6 (211 to +22)
Kenya +15 (+13 to +18) +11 (+8 to +14)
Malawi +9 (+2 to +15) +12 (+4 to +21)
Mali +12 (22 to +27) +4 (21 to +10)
Rwanda +32 (+22 to +42) +31 (+12 to +51)
Tanzania +7 (21 to +14) +2 (24 to +8)
Uganda +23 (+11 to +35) +16 (+1 to +31)
Zimbabwe +8 (+1 to +15) +5 (21 to +11)
Pooled
Crude +12 (+6 to +17) +11 (+7 to +15)
Weighted* +11 (+4 to +17) +9 (+4 to +14)
Lower middle-income
Cameroon +10 (24 to +24) +13 (24 to +31)
Côte d’Ivoire +13 (+8 to +19) +10 (0 to +20)
Nigeria +4 (213 to +21) 22 (214 to +9)
Zambia +11 (+9 to +13) +8 (+4 to +11)
Pooled
Crude +9 (+6 to +12) +7 (+4 to +10)
Weighted* +6 (+1 to +11) +5 (+1 to +9)
Upper middle-income
Botswana +9 (24 to +23) 21 (217 to +15)
Brazil +8 (28 to +24) +15 (0 to +29)
South Africa +9 (+8 to +11) +4 (+1 to +7)
Thailand +10 (+2 to +17) +6 (26 to +18)
Pooled
Crude +9 (+6 to +11) +4 (+1 to +7)
Weighted* +7 (+1 to +13) +6 (21 to +13)
High-income
Australia +10 (218 to +38) 23 (212 to +7)
Canada +7 (21 to +15) +16 (+12 to +20)
France +11 (+8 to +13) +9 (+3 to +15)
Italy +4 (23 to +11) +6 (23 to +14)
Spain +3 (21 to +7) +6 (+2 to +10)
USA +9 (+2 to +16) +13 (+6 to +20)
Pooled
Crude +9 (+6 to +11) +9 (+6 to +12)
Weighted* +7 (+4 to +11) +9 (+6 to +13)
Results from linear regression (model 1) based on 347,919 patients, with missing
values imputed using multiple imputation.
*Weighted by the number of patients on cART in the respective country, as
estimated by WHO.5
TABLE 3. Individual-Level and Country-Level Predictors of the
Median CD4 Cell Count at the Start of cART in 2009
Variable Median CD4 Cell Count (Cells/mL)
Sex
Male 164 (intercept, 140 to 189)
Female 23 (18 to 28)
Income group
Low 164 (intercept, 140 to 189)
Lower middle 213 (256 to 30)
Upper middle 222 (262 to 18)
High 112 (75 to 149)
Age group (yrs)
,30 164 (intercept, 140 to 189)
30 to ,40 216 (221 to 210)
40 to ,50 217 (224 to 210)
$50 23 (212 to 6)
National cART coverage (%)*
,40 144 (intercept, 103 to 185)
40 to ,60 10 (238 to 57)
60 to ,80 26 (258 to 46)
$80 88 (35 to 141)
Results from mixed effects linear regression (model 2) based on 55,007 patients
starting cART in 2009, missing values imputed using multiple imputation. Intercepts
and coefﬁcients (95% conﬁdence intervals) are shown. All models include calendar year,
age, gender, and income group. The intercept of 164 cells/mL corresponds to men in
low-income countries.
*Separate analysis based on 52,482 patients starting cART in 2009 in low-income
and middle-income countries (model 2). The intercept of 144 cells/mL corresponds to
men in low-income countries. Estimates of national cART coverage in 2009, based on
WHO 2006 guidelines were as follows25: Benin 72%, Democratic Republic of the
Congo 26%, Kenya 65%, Malawi 63%, Mali 65%, Rwanda .95%, Tanzania 44%,
Uganda 53%, Zimbabwe 49%, Cameroon 41%, Côte d’Ivoire 39%, Nigeria 31%, Zam-
bia 85%, Botswana .95%, Brazil 80%, South Africa 56%, and Thailand 76%.
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start of cART were missing in approximately 1 quarter of
patients, who were more likely to be from LIC and MIC and
in a more advanced stage of disease than patients with
measured CD4 cell counts. It is thus likely that our estimates
of median CD4 cell counts at cART initiation are biased
upward for these countries. Data from some countries were
limited to a small number of patients from a single clinic. We
decided to include these in descriptive analyses, but because
the data are probably not representative of all patients on
cART in those countries, we excluded them from analyses of
time trends and predictors of CD4 cell count at the start of
cART. In sensitivity analyses, we weighted individual
country data, with the aim of creating a data set that was
representative, within each income group, of the number of
patients on cART in each country, as estimated by WHO.5
Some of the data included in these sensitivity analyses may,
however, not be representative of all patients on cART in the
country. In particular, the clinics from LIC and MIC partici-
pating in IeDEA are mainly urban and capture data in elec-
tronic databases, indicating a higher level of resources. They
may more closely reﬂect best practice in urban settings than in
the country as a whole. Nevertheless, our study is a unique
source of information on trends and determinants of the CD4
cell count in adult patients starting cART across the globe.
In conclusion, our results illustrate the enormous
challenges that lie ahead. Despite the massive scale up of
cART in LIC, from 300,000 patients on cART in 2002 to 6.6
million by the end of 2010, the increases in median CD4 cell
count at the start of cART during this period have been
modest. In 2009, most patients in LIC and MIC and many
patients in HIC started cART with CD4 cell counts below 200
cells/mL, which means that they were already at high risk of
complications and had spent years at high risk of HIV trans-
mission. Substantial efforts and resources are needed to
achieve earlier implementation of cART globally. Finally,
continued monitoring of the CD4 cell count at which HIV-
positive patients start cART in LIC, middle-income countries,
and HIC is needed to evaluate the results of these efforts.
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